QRxPharma Ltd. has entered a licensing agreement with Paladin Labs, Inc. for the Canadian commercialization rights to MOXDUO, a patented, immediate release formulation of morphine and oxycodone.   Paladin will receive exclusive rights to commercialize MOXDUO in Canada and assumes responsibility for the New Drug Submission (NDS), product launch costs as well as ongoing marketing and sales efforts. QRxPharma will receive an up-front payment of $500,000, royalties, and as much as $25 million in mi...